Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
CMC Fiscal 2026 Q2 Earnings Call - Precast Acquisitions and TAG Drive Core EBITDA to $297.5M
CMC posted a blowout fiscal Q2 driven by operational fixes and two strategic precast acquisitions. Consolidated core EBITDA jumped 114% year over year to $297.5 million, helped by TAG productivity gai...
- Consolidated core EBITDA was $297.5 million in Q2, up 114% year over year, and core EBITDA margin rose to 14%, a 610 basis point improvement.
- Reported net earnings were $93 million, or $0.83 per diluted share; adjusted earnings were $130.1 million, or $1.16 per diluted share, after excluding certain acquisition and other items.
- CMC completed acquisitions of CP&P and Foley and entered the precast business, with precast contributing $33.6 million to Construction Solutions adjusted EBITDA in Q2.
- +17 more takeaways
REX American Resources Q4 & FY2025 Earnings Call - 45Z tax credit drives record EPS, One Earth expansion near completion
REX closed fiscal 2025 with record per-share earnings after recognizing roughly $28 million of 45Z tax credits and reporting all-time high annual ethanol volumes. The One Earth Energy expansion to 200...
- REX recognized approximately $28 million of 45Z tax credits in fiscal 2025 after regulations clarified, materially boosting Q4 and full-year results.
- Management states the realized 45Z benefit equates to roughly $0.10 per gallon on consolidated ethanol volumes for FY2025.
- One Earth Energy expansion is nearing completion, raising capacity to 200 million gallons per year, with testing and commissioning expected in fiscal 2026.
- +13 more takeaways
JBS 4Q 2025 Earnings Call - Record Revenue and Resilient Multi-Protein Platform Amid U.S. Cattle Tightness
JBS closed 2025 with record scale, reporting $23 billion in fourth quarter sales and $86 billion for the year, while management stressed that geographic and protein diversification insulated results f...
- Scale and record sales: Q4 revenue $23 billion, FY 2025 revenue $86 billion, the highest in company history.
- Mixed EBITDA metrics called out: CEO cited a Q4 EBITDA margin of 17.5%, while CFO reported adjusted EBITDA (IFRS) of $1.7 billion and a Q4 margin of 7.4% (U.S. GAAP adjusted EBITDA $1.5 billion, 6.5% margin).
- Profitability and earnings: Management reported net income around $450 million in Q4 and $2.0 billion for the year; CFO detailed Q4 net income $415 million (EPS $0.39) and adjusted FY net income of $2.2 billion (adjusted EPS $2.10).
- +12 more takeaways
H.B. Fuller Q1 2026 Earnings Call - Supply shock forces 10%+ global price hike, guidance raised as pricing offsets volume weakness
H.B. Fuller reported a defensible quarter, with adjusted EBITDA of $119 million, margins expanding as pricing, raw-material actions, and Project Quantum Leap restructuring more than offset a 6.6% orga...
- Organic revenue fell 6.6% year over year in Q1 2026, with pricing up 0.6% and volume down 7.2%.
- Adjusted EBITDA was $119 million, up 4% year over year, and adjusted EBITDA margin expanded 90 basis points to 15.4%.
- Management announced a minimum 10% global price increase, effective April 1, with higher adjustments for certain technologies and regions.
- +12 more takeaways
M-tron Industries Q4 FY2025 Earnings Call - 62% Backlog Surge, Rights Offering to Fund Defense-driven Expansion
M-tron closed FY2025 with a meaningful defense-led acceleration, a 62% jump in backlog to $76.4 million, and signs it is pivoting from organic growth to dealmaking. Q4 revenue was $14.2 million, up 11...
- Backlog jumped 62% year over year to $76.4 million at quarter end, driven primarily by defense programs and commercial avionics orders.
- Q4 revenue was $14.2 million, an 11.2% increase versus Q4 2024; full-year 2025 revenue was $54.4 million, also up 11.2% year over year.
- Q4 gross margin was 46.9% versus 47.2% a year earlier; full-year gross margin declined to 44.4% from 46.2% in 2024, with tariffs and an unfavorable new-product mix cited as the main drivers.
- +11 more takeaways
The Dixie Group, Inc. Q4 2025 Earnings Call - Gained Carpet Market Share While Cutting Costs and Eating Tariffs
Dixie delivered a defensive quarter: sales slipped modestly, yet margins improved materially as the company squeezed costs and leaned on reshoring investments. Net sales for Q4 fell 1.4% year over yea...
- Net sales Q4 2025 of $63.487 million were down 1.4% versus Q4 2024, full year 2025 sales of $257.429 million were down 2.9% year over year.
- Net loss improved: Q4 2025 loss of $3.0 million versus $7.198 million a year ago, full year 2025 net loss of $7.615 million versus $13.0 million in 2024.
- Gross margins rose to 27% for both the quarter and full year 2025, up from 21.7% in the prior year quarter and 24.7% for FY 2024, driven by cost reductions and profit improvement initiatives.
- +12 more takeaways
Stran & Company FY2025 Earnings Call - 40.6% Revenue Jump and Break-Even EBITDA, Tariffs Still Pinch Margins
Stran delivered a sharp growth year in FY2025, reporting $116.2 million in revenue, up 40.6% year over year, driven by a full-year consolidation of the Gander Group assets and 12.9% organic expansion ...
- Revenue grew 40.6% to $116.2 million in FY2025, up from $82.7 million in 2024.
- Organic growth in the core promotional products business was 12.9%, indicating healthy underlying demand from existing clients.
- Stran recorded $34.2 million in gross profit, equal to 29.5% of sales, down from 31.2% last year due to mix and the consolidated loyalty business.
- +13 more takeaways
WhiteFiber, Inc. Q4 2025 Earnings Call - Retrofit Speed and a De-risked NC1 Backed by an Investment-Grade Offtaker
WhiteFiber leaned into its retrofit-first playbook in Q4, converting Montreal 3 from an industrial factory into a live data center in roughly six months and bringing on Cerebras as a tenant. The compa...
- Completed IPO in 2025 and set up standalone public-company reporting and governance.
- Montreal 3 delivered in Q4 2025 via a retrofit of an industrial factory in about six months, supporting Cerebras as a colocation tenant.
- Company is exercising a purchase option on Montreal 3 for approximately CAD 24 million, which will cut lease payments by about CAD 3.1 million annually.
- +12 more takeaways
BRP Inc. Q4 FY2026 Earnings Call - Inventory Right-Sized and New Models Fuel Share Gains, Yet Tariffs and Oil Pressure Narrow Margins
BRP closed fiscal 2026 with a clean finish, reporting CAD 8.4 billion in revenue, normalized EBITDA of CAD 1.1 billion and more than CAD 900 million of free cash flow. Management says dealer inventori...
- New CEO Denis Mansueto has been in the role two months, praises BRP’s product pipeline and culture, and plans no immediate strategic overhaul while preparing a longer term plan.
- FY2026 results beat guidance: revenue CAD 8.4 billion, normalized EBITDA CAD 1.1 billion, normalized EPS CAD 5.21, and free cash flow above CAD 900 million.
- Q4 revenue grew 16% to about CAD 2.5 billion; normalized EBITDA rose 47% to CAD 364 million and normalized EPS doubled to CAD 2.21 in the quarter.
- +12 more takeaways
Innate Pharma Full Year 2025 Earnings Call - IPH4502 shows post-PADCEV clinical activity, lacutamab Phase III cleared but financing needed
Innate Pharma doubled down on three priority assets, signalling a leaner company focused on late-stage value. The big technical wins are clear: FDA cleared the TELLOMAK 3 protocol for lacutamab in CTC...
- Company strategy: Innate has prioritized three high-value programs, lacutamab, IPH4502, and monalizumab, and is trimming organization costs to focus capital on late-stage development and ADC platform work.
- Lacutamab regulatory progress: FDA cleared the TELLOMAK 3 Phase III protocol for CTCL, with planned initiation in the second half of 2026, contingent on securing financing.
- TELLOMAK 3 design: Two independent randomized cohorts for Sézary syndrome and mycosis fungoides, primary endpoint is PFS by blinded independent central review, secondary endpoints include OS for SS and QoL/pruritus for MF.
- +13 more takeaways